Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation

Panelists discuss the clinical scenario of newly diagnosed acute myeloid lymphoma (AML) with an NPM1 mutation, exploring treatment strategies and key considerations for managing this patient population.

EP: 1.All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

EP: 2.AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

EP: 3.Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

EP: 4.Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

Now Viewing

EP: 5.Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation

EP: 6.Clinical Scenario: TP53- Mutant AML

Recent Videos